Inventor
Stephen Douglas Barrett
Inventor
Hartland, MI, US
Overview
Patents· 42 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
A61KPreparations for medical, dental or toiletry purposes19%
C07CAcyclic or carbocyclic compounds13%
A61LMethods or apparatus for sterilising materials or objects in general6%
C07BGeneral methods of organic chemistry1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
C07HSugars1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
PatentTitleYear
10,729,810Methods, systems, and compositions for promoting bone growth202010,556,862Difluorolactam compounds as EP20209,938,289Therapeutic pyrazolyl thienopyridines20189,914,725'Methods of synthesizing a difluorolactam analog'20189,701,630'Difluorolactam compositions for EP4-mediated osteo related diseases and conditions'20179,688,627'Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20179,676,712'Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20179,487,478'Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20169,440,919'Difluorolactam compositions for EP4-mediated osteo related diseases and conditions'20169,260,450'Therapeutic pyrazolyl thienopyridines'20169,180,116'Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions'20159,126,973'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20159,120,820'Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins'20159,090,625'Therapeutic pyrazolyl thienopyridines'20158,536,185'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20138,455,512'Therapeutic pyrazolyl thienopyridines'20138,450,326'Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases'20138,063,240'Prostaglandin E1 and E2 analogs for the treatment of various medical conditions'20117,964,612'Therapeutic pyrazolyl thienopyridines'20117,799,823'Androgen modulators'20107,674,819'Androgen modulators'20107,470,715'Estrogen modulators'20087,411,001'Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids'20087,169,816'4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors'20077,160,915'N-methyl-substituted benzamidazoles'20077,078,438'N-(4 substituted phenyl)-anthranilic acid hydroxamate esters'20067,030,119'Method for treating chronic pain using MEK inhibitors'20067,019,033'2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives'20066,960,614'Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids'20056,891,066'N-(4-substituted phenyl)-anthranilic acid hydroxamate esters'20056,821,963'4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors'20046,770,778'N-(4-substituted phenyl)-anthranilic acid hydroxamate esters'20046,750,217'Benzenesulfonamide derivatives and their use as MEK inhibitors'20046,545,030'1-heterocycle substituted diarylamines'20036,506,798'4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors'20036,492,363'2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives'20026,469,004'Benzoheterocycles and their uses as MEK inhibitors'20026,440,966'Benzenesulfonamide derivatives and their use as MEK inhibitors'20026,310,060'2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors'20016,251,943'Method of treating or preventing septic shock by administering a MEK inhibitor'20015,534,522'(R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent'19965,346,911'Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–2010Patents assigned to WARNER LAMBERT CO (21)· patent assignee history
1994Based in Ferndale, MI, US· patent location history
1996–2006Based in Livonia, MI, US· patent location history
2003–2020Based in Hartland, MI, US· patent location history
2011–2020Patents assigned to CAYMAN CHEMICAL CO INC (13)· patent assignee history
2011–2013Patents assigned to BARRETT STEPHEN D (2)· patent assignee history
2015–2018Patents assigned to THESAN PHARMACEUTICALS INC (3)· patent assignee history
2016–2020Patents assigned to MYOMETRICS LLC (5)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| WARNER LAMBERT CO | 21 | 1994–2010 |
| CAYMAN CHEMICAL CO INC | 13 | 2011–2020 |
| MYOMETRICS LLC | 5 | 2016–2020 |
| THESAN PHARMACEUTICALS INC | 3 | 2015–2018 |
| BARRETT STEPHEN Dself | 2 | 2011–2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Hartland, MI, US | 30 | 2003–2020 |
| Livonia, MI, US | 11 | 1996–2006 |
| Ferndale, MI, US | 1 | 1994 |